Pfizer Inc. (NYSE:PFE) Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 31.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,036 shares of the biopharmaceutical company’s stock after purchasing an additional 84,536 shares during the quarter. NEOS Investment Management LLC’s holdings in Pfizer were worth $9,286,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in PFE. Amica Mutual Insurance Co. grew its stake in shares of Pfizer by 44.7% during the fourth quarter. Amica Mutual Insurance Co. now owns 157,064 shares of the biopharmaceutical company’s stock valued at $4,167,000 after acquiring an additional 48,541 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of Pfizer by 34.8% in the fourth quarter. UniSuper Management Pty Ltd now owns 349,745 shares of the biopharmaceutical company’s stock worth $9,279,000 after acquiring an additional 90,289 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Pfizer by 8.1% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 9,013,007 shares of the biopharmaceutical company’s stock valued at $239,656,000 after purchasing an additional 674,556 shares during the last quarter. Korea Investment CORP grew its stake in Pfizer by 12.2% during the 4th quarter. Korea Investment CORP now owns 4,276,631 shares of the biopharmaceutical company’s stock valued at $113,459,000 after purchasing an additional 465,700 shares in the last quarter. Finally, Tyler Stone Wealth Management increased its holdings in Pfizer by 42.7% during the 4th quarter. Tyler Stone Wealth Management now owns 44,469 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 13,313 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.19 on Thursday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $142.88 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s fifty day moving average price is $26.12 and its two-hundred day moving average price is $26.98.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.